Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential ef
about
MiRNA-Sequence Indicates That Mesenchymal Stem Cells and Exosomes Have Similar Mechanism to Enhance Cardiac Repair.A Frailty Index Based On Deficit Accumulation Quantifies Mortality Risk in Humans and in Mice.Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue.Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Stem Cell Transplantation for Frailty.Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
P2860
Q37624958-2164CA89-914D-4EF3-BEAC-7AD7BBD27695Q37654717-6AF106DF-63EE-480C-B713-E7F4B9444FE3Q38874116-AB20E6AA-D059-41BD-AFFA-91E41DD2549DQ39150558-51942BD3-74C8-465C-87B3-7F43E71C5818Q47620195-334EFE90-4543-4A60-B635-34B7E7ECB8F3Q47740786-2D34262D-C556-40C1-8609-5B4AB0AC1E4BQ50203037-0274411B-2C2A-445E-8EB7-47382A866A40
P2860
Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential ef
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rationale and design of the al ...... te the safety and potential ef
@en
Rationale and design of the al ...... te the safety and potential ef
@nl
type
label
Rationale and design of the al ...... te the safety and potential ef
@en
Rationale and design of the al ...... te the safety and potential ef
@nl
prefLabel
Rationale and design of the al ...... te the safety and potential ef
@en
Rationale and design of the al ...... te the safety and potential ef
@nl
P2093
P2860
P921
P356
P1433
P1476
Rationale and design of the al ...... in patients with aging frailty
@en
P2093
Aisha Khan
Alan W Heldman
Ariel Wolf
Bangon Longsomboon
Darcy L DiFede
Joshua M Hare
Marietsy V Pujol
Maureen H Lowery
Pascal J Goldschmidt-Clermont
Samuel Golpanian
P2860
P304
11899-11912
P356
10.18632/ONCOTARGET.7727
P407
P577
2016-03-01T00:00:00Z